Home » Stocks » BGNE

BeiGene Ltd. (BGNE)

Stock Price: $336.68 USD 13.01 (4.02%)
Updated May 18, 2021 2:13 PM EDT - Market open
Market Cap 28.71B
Revenue (ttm) 862.69M
Net Income (ttm) -1.17B
Shares Out 91.80M
EPS (ttm) -13.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 18
Last Price $336.68
Previous Close $323.67
Change ($) 13.01
Change (%) 4.02%
Day's Open 324.92
Day's Range 324.33 - 337.85
Day's Volume 48,934
52-Week Range 155.16 - 388.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 week ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2021.

1 week ago - Business Wire

BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibr...

Other stocks mentioned: JNJ
2 weeks ago - Benzinga

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene announces positive interim results in Phase 3 ALPINE trial comparing BRUKINSA® (zanubrutinib) to ibrutinib in chronic lymphocytic leukemia.

2 weeks ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

1 month ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

1 month ago - Business Wire

BeiGene Ltd (NASDAQ: BGNE) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring supplemental oxygen without mechanical ventilation. The s...

1 month ago - Benzinga

MISSISSAUGA, Ontario--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines ...

1 month ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worl...

1 month ago - Business Wire

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

1 month ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines, tod...

1 month ago - Business Wire

Investors often look to top fund managers to glean information on the best strategies and generate new investment ideas.

Other stocks mentioned: ABNB, ASML, CYH, GS, SEAS, SIEN
1 month ago - GuruFocus

In Amgen Inc.'s (NASDAQ:AMGN) recent agreement to buy small cancer drug developer Five Prime Therapeutics Inc. (NASDAQ:FPRX) for nearly $2 billion, there seems to be a message for investors in other sma...

Other stocks mentioned: AMGN, BMY, FPRX
1 month ago - GuruFocus

Hutchison China MediTech (NASDAQ: HCM) has initiated a Phase 1b/2 study of surufatinib combined with BeiGene Ltd's (NASDAQ: BGNE) tislelizumab in patients with advanced solid tumors in the U.S. and Euro...

Other stocks mentioned: HCM
1 month ago - Benzinga

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021

2 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

2 months ago - Business Wire

With the trading day about halfway over, the broad markets were pushing higher on the day.

Other stocks mentioned: BMBL, NEE, WPM, AKBA, ARAV, IMO, IOVA ...
2 months ago - 24/7 Wall Street

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

2 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström's Macroglobulinemia

2 months ago - Business Wire

The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a 10% drop over the last ten trading days, while it's down 6%...

2 months ago - Forbes

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces Closing of Collaboration with Novartis to Develop & Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe ...

2 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

2 months ago - Business Wire

BOSTON & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 ...

3 months ago - Business Wire

The FDA has accepted for review BeiGene Ltd's (NASDAQ: BGNE) supplemental marketing application seeking approval for BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström's Macrog...

3 months ago - Benzinga

CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (Zanubrutinib) in Waldenström's Macroglobulinemia

3 months ago - Business Wire

Week In Review: Matridx Raises $32 Million For AI/CRISPR-Cas Pathogen Metagenomics Diagnostic Devices

Other stocks mentioned: NVS
3 months ago - Seeking Alpha

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene Announces Positive Topline Results for Global Phase 3 Trial of Tislelizumab in Esophageal Squamous Cell Carcinoma

3 months ago - Business Wire

HEMEL HEMPSTEAD, England & BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EUSA Pharma (UK) Limited and BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) today announced that the Biologics License Applicati...

3 months ago - Business Wire

BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. Inmagene in-licensed global rights to four novel pre-clinical immun...

Other stocks mentioned: NVS
4 months ago - Seeking Alpha

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

4 months ago - Zacks Investment Research

Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment. Earlier this week, Novartis signed on to commercialize the drug.

4 months ago - Investors Business Daily

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene's anti-PD-1 antibody received approval in China in first-line advanced squamous non-small cell lung cancer.

4 months ago - Business Wire

Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.

Other stocks mentioned: NVS
4 months ago - Zacks Investment Research

BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tislelizumab. BeiG...

Other stocks mentioned: AMRX, TTOO
4 months ago - Benzinga

Beigene stock jumped Tuesday on a cancer drug development deal with Novartis worth up to $2.2 billion, as Vir Biotechnology also announced a hepatitis B tie-up with Gilead Sciences. The post Beigene Sur...

Other stocks mentioned: NVS
4 months ago - Investors Business Daily

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and Novartis enter into a collaboration to develop, manufacture and commercialize tislelizumab, BeiGene's anti-PD-1 antibody.

4 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--Strand Therapeutics and BeiGene entered an option and license agreement aimed at developing, commercializing Strand's mRNA treatments for sol...

4 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative m...

4 months ago - Business Wire

BEIJING, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces inclusion of three innovative oncology products in China National Reimbursement Drug List (NRDL).

4 months ago - Business Wire

Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma Trial Represents First-Ever Phase 0 for Newly Diagnosed Patients with Glioblastoma

5 months ago - GlobeNewsWire

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces that BLINCYTO® (blinatumomab) for injection has been approved in China in relapsed/refractory B-cell precursor ALL.

5 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene announces clinical data on BTK inhibitor BRUKINSA (zanubrutinib) in B-cell malignancies and Waldenström's at the 62nd ASH annual mee...

5 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #ASH20--BeiGene presents data on BTK inhibitor BRUKINSA in marginal zone lymphoma and chronic lymphocytic leukemia at the 62nd ASH Annual Meeting.

5 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

5 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medi...

5 months ago - Business Wire

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $bgne #beigene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative m...

5 months ago - Business Wire

BeiGene is planning an IPO on the Shanghai Star Exchange that could raise up to $2.5 billion. BeiGene announced China approval to market Xgeva (denosumab) to prevent skeletal-related events (SREs) in pa...

5 months ago - Seeking Alpha

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene announces the second approval of XGEVA® (denosumab) in China.

5 months ago - Business Wire

Pharmaceuticals is the only sector that has all three characteristics foreign investors are looking for in Chinese investments: an industry that will consolidate, pro-growth policy reform and support an...

Other stocks mentioned: HCM
6 months ago - GuruFocus

CAMBRIDGE, Mass. & BEIJING, China--(BUSINESS WIRE)---- $BGNE #BGNE--Global Phase 3 trial of tislelizumab in second- or third-line non-small cell lung cancer met the primary endpoint at interim analysis.

6 months ago - Business Wire

About BGNE

BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA... [Read more...]

Industry
Biotechnology
IPO Date
Feb 3, 2016
CEO
John Oyler
Employees
5,400
Stock Exchange
NASDAQ
Ticker Symbol
BGNE
Full Company Profile

Financial Performance

In 2020, BeiGene's revenue was $308.87 million, a decrease of -27.87% compared to the previous year's $428.21 million. Losses were -$1.60 billion, 68.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for BeiGene stock is "Buy." The 12-month stock price forecast is 361.36, which is an increase of 7.33% from the latest price.

Price Target
$361.36
(7.33% upside)
Analyst Consensus: Buy